Loading...
XPAR
LBIRD
Market cap687mUSD
Jul 10, Last price  
27.35EUR
1D
0.18%
1Q
23.76%
Jan 2017
748.47%
Name

Lumibird SA

Chart & Performance

D1W1MN
XPAR:LBIRD chart
P/E
43.03
P/S
2.64
EPS
0.64
Div Yield, %
Shrs. gr., 5y
0.24%
Rev. gr., 5y
12.03%
Revenues
229m
+8.79%
44,456,00056,087,00059,780,00050,492,00055,466,00052,995,00063,227,00063,973,00037,817,000101,796,000112,653,000129,505,000162,468,000194,294,000206,554,000210,057,000228,529,000
Net income
14m
+145.83%
-6,720,000733,0001,218,000-3,495,000-339,000-1,105,0002,126,000646,0001,740,0008,075,0008,820,0005,638,00013,858,00011,353,0007,126,0005,695,00014,000,000
CFO
29m
-15.61%
5,914,0004,404,0001,413,000-1,599,0002,073,000253,0007,787,0004,004,0007,391,00012,079,00019,472,00013,123,00026,575,0001,427,00020,667,00034,366,00029,003,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

A global leader, Lumibird S.A. specializes in the development, manufacturing, and distribution of a wide array of laser technologies. Its sophisticated laser products are deployed worldwide across scientific, industrial, and medical sectors. The company's operations are divided into two key segments: Photonics and Medical. Within its Photonics division, Lumibird offers an extensive portfolio, including solid-state lasers, high-power laser diodes, fiber lasers, and related amplifiers and components. This segment also provides advanced photonics solutions for time-of-flight LiDAR, range-finding, and Doppler LiDAR systems for wind measurement. These offerings are critical for industrial and scientific advancements, defense and space operations, and diverse LiDAR sensing needs. Concurrently, the Medical division delivers comprehensive medical and ophthalmological solutions, encompassing everything from diagnosis to laser-based therapies. Established in 1970, Lumibird S.A. maintains its corporate headquarters in Lannion, France.
IPO date
Sep 30, 1997
Employees
604
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT